 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Neurobiological Technologies, Inc.
 |
Neurobiological Technologies, Inc. |
 |
 |
 |
PROFILE |
 |
Neurobiological Technologies is rich in ideas, but cash poor. The development-stage company's biggest woes revolve around a lack of funds to develop its drug candidates Memantine and Xerecept. Memantine's ability to act on neurons is being evaluated for the treatment of brain injury, AIDS-related dementia, and Alzheimer's disease. Germany's Merz + Co. markets Memantine in that country and has licensed marketing rights in other countries to Forest Laboratories. Its other candidate, Xerecept, reduces brain swelling associated with tumors and brain injury. The FDA has granted Xerecept orphan drug status, giving the company market exclusivity for seven years and making it eligible for federal research grants.
COMPETITION |
 |
Advanced Neuromodulation Systems, Inc. (ANSI)
Centaur Pharmaceuticals, Inc. (dossier)
StemCells, Inc. (STEM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 0.00
Employees: 11
Revenue per employee: $0.00
KEY PEOPLE |
 |
Paul E. Freiman
CEO
Paul E. Freiman
CFO
CONTACT INFO |
 |
1387 Marina Way South
Richmond, CA 94804
US
Phone: 510-262-1730
Fax: 510-262-0204
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |